Remegal (beprodon) / MarcoPolo Pharma - LARVOL DELTA

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades. (PubMed, Drugs) - "Compounds whose development was terminated include atimepazole, beprodone, cannabidivarin, carabersat, conantokin-G, dezinamide, elpetrigine, flunarizine, fluorofelbamate, ICA-105665, isovaleramide, JNJ-40411813, losigamone, naluzotan, padsevonil, pitolisant, ralitoline, remacemide, safinamide, soretolide, talampanel, tonabersat, T2000, T2007, valnoctamide, valrocemide, VX-765, zandatrigine, zuranolone, and 534U87. In some instances, failure to pursue an epilepsy indication could be explained by prioritization of development for other neurological or psychiatric conditions. This may reflect the perception of the drug market for common epilepsies being relatively crowded, and only attractive for compounds with outstanding safety or efficacy advantages over existing medications."

Journal • Review • CNS Disorders • Epilepsy • Psychiatry

Radiocarbon dates and Bayesian modeling support maritime diffusion model for megaliths in Europe. (PubMed, Proc Natl Acad Sci U S A) - "...We applied a Bayesian statistical approach to 2,410 currently available radiocarbon results from megalithic, partly premegalithic, and contemporaneous nonmegalithic contexts in Europe to resolve this long-standing debate...We found decisive support for the spread of megaliths along the sea route in three main phases. Thus, a maritime diffusion model is the most likely explanation of their expansion."

Journal